BioNexus Gene Lab Corp. Equity Securities, FV-NI, Realized Gain (Loss)
BioNexus Gene Lab Corp. (BGLC) reported Equity Securities, FV-NI, Realized Gain (Loss) of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-05-15
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was -$2.72K, a 146.72% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was $0.00.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-06-30 was -$27.26K.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was -$93.97K, a 235.25% decline from fiscal 2024.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was $69.48K.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | -$2.72K derived: sum of 2 quarters · filed 2026-05-15 | -$2.72K derived: sum of 3 quarters · filed 2026-05-15 | -$29.98K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | -$2.72K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$2.72K derived: sum of 2 quarters · filed 2026-04-14 | -$29.98K derived: sum of 3 quarters · filed 2026-04-14 | -$93.97K 10-K · filed 2026-04-14 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$27.26K derived: sum of 2 quarters · filed 2025-11-14 | -$91.24K 10-Q · filed 2025-11-14 | -$85.42K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | -$27.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$91.24K 10-Q · filed 2025-08-18 | -$85.42K derived: sum of 3 quarters · filed 2026-05-15 | -$94.65K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | -$63.98K 10-Q · filed 2026-05-15 | -$58.16K derived: sum of 2 quarters · filed 2026-05-15 | -$67.39K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $5.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$3.41K derived: sum of 2 quarters · filed 2026-04-14 | $69.48K 10-K · filed 2026-04-14 | |
| 2024-09-30 | -$9.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $63.65K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $72.88K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |